SUZHOU, China -- Alphamab Oncology, a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of world-class innovative therapeutics for cancer treatment, today announced that Dr. Ting Xu, Chairman of the Board and Chief Executive Officer of Alphamab Oncology, is invited to give a presentation about the company and its clinical pipeline progress at the upcoming 37th Annual J.P. Morgan Healthcare Conference, which will be held on January 7-10, 2019 in San Francisco, according to PRNewswire on January 5.
Dr. Ting Xu's presentation on Alphamab Oncology is scheduled for 1:30 pm on Wednesday, January 9 US Pacific Standard Time (PST), and will be live webcast through the following link https://jpmorgan.metameetings.net/events/healthcare19/sessions/25574-alphamab/webcast. The playback record of the live webcast will also be available for access through the link within 90 days after the Conference.
Alphamab Oncology is also invited to join the panel discussion at the Conference session of "China Biotech – Policy, Innovation, Entrepreneurship and Strategic Development" at 12:00 – 13:00 pm US PST on January 9, 2019.
About Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms including bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/immunology, and we are striving to develop next-generation or best-in-class medicines to address global unmet medical needs. Visit http://www.alphamabonc.com for more information.
Contacts:
Alphamab Oncology
Tingting Zhang, Extension 8807
tingtingzhang@alphamabonc.com
